SCHEMBL564985

SCHEMBL564985

Nc1c(O)cccc1Nc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.55
ALDH1A1 P00352 7/20 0.55
GAA P10253 5/20 0.55
KDM4E B2RXH2 5/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
LMNA P02545 2/20 0.55
CYP1A2 P05177 2/20 0.55
CYP2C9 P11712 2/20 0.55
CYP2C19 P33261 2/20 0.55
CYP2D6 P10635 1/20 0.55
TDP1 Q9NUW8 4/20 0.52
GLA P06280 1/20 0.52
RECQL P46063 1/20 0.52
CXCR2 P25025 1/20 0.49
HSD17B10 Q99714 5/20 0.47
ALOX15 P16050 4/20 0.47
CYP3A4 P08684 3/20 0.47
HPGD P15428 3/20 0.47
TSHR P16473 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL564616 0.85 EGFR (0.47) MAPTALDH1A1GAAKDM4EMEN1
SCHEMBL29720861 0.81 CXCR2 (0.68) MAPTALDH1A1GAAKDM4EMEN1
SCHEMBL1008928 0.81 CXCR2 (0.68) MAPTALDH1A1GAAKDM4EMEN1
SCHEMBL27294589 0.79 MAPT (0.56) MAPTALDH1A1GAAKDM4EMEN1
SCHEMBL31484215 0.79 MAPT (0.72) MAPTALDH1A1GAAKDM4EMEN1
SCHEMBL16934632 0.79 MAPT (0.72) MAPTALDH1A1GAAKDM4EMEN1
SCHEMBL27435565 0.79 CXCR2 (0.66) MAPTALDH1A1GAAKDM4EMEN1
SCHEMBL1939854 0.77 FABP4 (0.68) MAPTALDH1A1GAAKDM4EMEN1
SCHEMBL10741108 0.77 CXCR2 (0.63) MAPTALDH1A1GAAKDM4EMEN1
SCHEMBL11000813 0.77 CXCR2 (0.63) MAPTALDH1A1GAAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115108994-B Tergolian intermediate and preparation method and application thereof 江苏威奇达药业有限公司 2024-05-31 CN claimed
CN-115108994-A Tegolrazan intermediate and preparation method and application thereof 江苏威奇达药业有限公司 2022-09-27 CN claimed
CN-115108994-B Tergolian intermediate and preparation method and application thereof 江苏威奇达药业有限公司 2024-05-31 CN disclosed
WO-2023095543-A1 ORGANIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT キヤノン株式会社 2023-06-01 WO disclosed
CN-115108994-A Tegolrazan intermediate and preparation method and application thereof 江苏威奇达药业有限公司 2022-09-27 CN disclosed
US-8674029-B2 Method of preparing stabilized polymeric systems using polymeric peroxides Sunocs LLC (US) 2014-03-18 US disclosed
US-20120035307-A1 PROCESS FOR MAKING STABLIZED POLYMERIC SYSTEMS WITH NANOSTRUCTURES SONG CHENGQIAN (US) 2012-02-09 US disclosed
US-20120035315-A1 METHOD OF PREPARING STABLIZED POLYMERIC SYSTEMS USING POLYMERIC PEROXIDES SONG CHENGQIAN (US) 2012-02-09 US disclosed
US-7498467-B2 Antioxidant and bisaminophenol derivative IDEMITSU KOSAN CO., LTD. (JP) 2009-03-03 US disclosed
US-20080161608-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2008-07-03 US disclosed
US-20060208227-A1 Antioxidant and bisaminophenol derivative IDEMITSU LOSAN CO., LTD (JP) 2006-09-21 US disclosed
EP-1612254-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE IDEMITSU KOSAN COMPANY LIMITED (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161608-A1 ANTIOXIDANT AND BISAMINOPHENOL DERIVATIVE CBR1, CBR3, HMOX1 MAPT 3886/4885ALDH1A1 204/4885GAA 3993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.